NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Asoka Lifescience Limited

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Asoka Lifescience Unveils New Poly-Herbal Asthma Medicine to Fight Asthma and Other Lung Problems - Managing asthma is easier now. World's first poly-herbal mouth dissolving tablet for respiratory distress has been brought out by Asoka Lifescience Limited after rigorous research and development by Jadavpur University
Asoka Lifescience Unveils New Poly-Herbal Asthma Medicine to Fight Asthma and Other Lung Problems

 

NewswireTODAY - /newswire/ - Kolkata, West Bengal, India, 2008/09/10 - Managing asthma is easier now. World's first poly-herbal mouth dissolving tablet for respiratory distress has been brought out by Asoka Lifescience Limited after rigorous research and development by Jadavpur University.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Asoka Lifescience Limited offers a first-of-its-kind Ayurvedic remedy for respiratory distress in patients of all ages. The new drug called Res-Q launched by Asoka Lifescience will cater to the growing number of patients with lung problems including a great percentage of children. The drug is made from new molecules by using medicinal herbs and incorporating a novel drug delivery system to render maximum efficacy.
“Our country has a vast knowledge base of Ayurveda whose potential is only being realised in the recent years. However, the drug delivery system used for administering the medicine to the patient is traditional and out-of-date resulting in reduced efficacy of the drug,” remarked Sourav Roy, Managing Director, Asoka Lifescience Limited. “We thought of coming up with a unique remedy of respiratory problems by blending the best of both- the tradition of Ayurveda and the technology of modern medicine.”

The drug is the outcome of rigorous research and development undertaken by the Department of Pharmaceutical Technology, Jadavpur University. Abbies Webiana, a universally prescribed herb for respiratory distress is one of the key ingredients of Res-Q. Based on a poly-herbal composition, Res-Q is a mouth dissolving drug that mixes with the juices secreted by the salivary glands and dissolves completely within fifteen minutes of putting in the mouth. Thus the drug never makes it to the stomach and the vital constituents are not absorbed by the various digestive juices secreted within the metabolic system of the body.
“Our country has the second highest mortality rate of asthma, one of the primary respiratory ailments we are targeting,” Mr. Roy went on to say. “We don’t claim our product to be a miracle drug that will cure asthma completely, but we are quite confident that Res-Q will ensure relief from attacks much faster and minimize them in the long run if taken on a regular basis.”

Res-Q comes in a strip of ten tablets, moderately priced to make it affordable among all the sections of the society. Many other research based drugs for chronic as well as fatal ailments are lined up for launch in the coming months.

The drug has been distributed among all the major chemist shops throughout the state of West Bengal and an entire team of aggressive sales professionals has been formed to meet the needs of distributors across the state. Besides the conventional marketing strategies, a non-profit organization called Asoka Welfare Society has also been formed up and ahelpline has been formed where queries on asthma and other respiratory ailments will be answered.The concerned person needs to send an SMS. He/she must write 'LUNG' and send it to 5676775. The associates of Asoka Welfare Society will get back to the person within 48 hours.

About Asoka Lifescience Limited

Asoka Lifescience Limited (asokalife.in) is a growing research based pharmaceutical company. The brainchild of young entrepreneur Sourav Roy, it is formed with the vision of ‘curing by caring’ for its patients. In the growing Indian pharmaceutical market, Asoka Lifescience is confident of holding centre stage in the coming years by delivering remedies of chronic ailments to a diverse cross section of the demographics. In order to provide new molecules for curing certain chronic ailments, a MoU has been signed with the Department of Pharmaceutical Technology, Jadavpur University.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Asoka Lifescience Limited

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Asoka Lifescience Unveils New Poly-Herbal Asthma Medicine to Fight Asthma and Other Lung Problems

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Sourav Roy - AsokaLife.in 
+91 33 25740566 info[.]asokalife.in
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Asoka Lifescience Limited securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Asoka Lifescience Limited / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

NEC and Chugai Pharmaceutical Use AI to Potentially Enhance Cancer Treatment
BASF Strengthens its Commitment to the Biopharma and Pharmaceutical Ingredients Industries through A New Investment in North America
ONO PHARMA Presents Positive Results from Pivotal Trial in U.S. Patients with Relapsed or Refractory PCNSL At 2025 ASCO Annual Meeting
SCHOTT Pharma Expands Ready-to-use Portfolio with Sterile 1.5 ml Cartridge
Ono Commences Research Collaboration with Jorna Therapeutics to Generate Novel RNA Editing Therapeutics
SCHOTT Pharma Opens Production Facility in Serbia to Strengthen Competitiveness in Europe
NEC Has Developed Technologies that Enable A Secure Workflow for Personalized Cancer Vaccines and Has Proven their Capabilities
BASF Aroma Ingredients Innovates with Two New Isobionics® Biotech Flavor Ingredients
Federal Government Invests .9 Million in STEMCELL Technologies Canada, Inc.
Ono Enters into License Agreement with Ionis Pharmaceuticals for Sapablursen for the Treatment of Polycythemia Vera
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab & hyaluronidase-nvhy) Injection
NEC Announces Interim Results from Phase 1 Clinical Trial of NECVAX-NEO1
SCHOTT Pharma Unveils Innovative Nest Design for Ready-to-use Cartridges

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2025 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)